<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03892824</url>
  </required_header>
  <id_info>
    <org_study_id>CL-326</org_study_id>
    <nct_id>NCT03892824</nct_id>
  </id_info>
  <brief_title>Carotid Artery Implant for Preventing Stroke in Atrial Fibrillation Patients Taking Oral Anticoagulants</brief_title>
  <acronym>CAPTURE2</acronym>
  <official_title>Carotid Artery ImPlant for Trapping UpstReam Emboli (CAPTURE 2) for Preventing Stroke in Atrial Fibrillation Patients Taking Oral Anticoagulants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Javelin Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genae</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Javelin Medical</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the safety and performance of the Vine™ Embolic Protection System&#xD;
      (embolic filtering device) in atrial fibrillation (AF) patients on top of oral anticoagulants&#xD;
      (OAC), and remain at high risk for stroke recurrence. All patients will receive bilateral&#xD;
      implants in the common carotid arteries&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Vine™ filter (Vine™ or implant) is a permanent carotid filter designed for stroke&#xD;
      prevention in AF patients taking OAC at high stroke risk (CHA2DS2-VASc ≤ 4 and stroke&#xD;
      history). This patient population accounts for ~20% of the entire AF population, which is&#xD;
      ~300K/year in the United State and EU. The implant is designed to exclude emboli &gt; 1.2mm in&#xD;
      size from reaching the anterior circulation. In AF patients, approximately 80% of strokes are&#xD;
      total or partial anterior circulation strokes caused by occlusions of the main branches of&#xD;
      the Circle of Willis, mainly M1-2, and rarely A1-2. The diameter of these branches, in the&#xD;
      majority of cases, is &gt; 1.5 mm&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 13, 2019</start_date>
  <completion_date type="Anticipated">June 2024</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants that had Ischemic Stroke and/or Hemorrhagic stroke and/or implantation procedure complications</measure>
    <time_frame>30 days from implantation procedure</time_frame>
    <description>Major Adverse Events (MAEs) within 30 days of the final index (implantation) procedure, defined as the composite that includes any of the following:&#xD;
Any ischemic stroke with ischemic foci confined to the territories of Vine™ implanted arteries&#xD;
Hemorrhagic stroke or major hemorrhage while receiving additional antithrombotic therapy required for Vine™ implantation&#xD;
Any Vine™ or Vine™ implantation procedure-related complication that requires surgery or endovascular treatment, or results in death or major disability</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants that had Ischemic Stroke and/or Hemorrhagic stroke and/or Device complications.</measure>
    <time_frame>one and two years from implantation procedure</time_frame>
    <description>Any ischemic stroke with ischemic foci confined to the territories of Vine™ implanted arteries&#xD;
Hemorrhagic stroke or major hemorrhage while receiving additional antithrombotic therapy required for Vine™ implantation&#xD;
Any Vine™ or Vine™ implantation procedure-related complication that requires surgery or endovascular treatment, or results in death or major disability</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of properly positioned implants</measure>
    <time_frame>30 days from implantation procedure</time_frame>
    <description>proper implant position in each common carotid artery (CCA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants that had disabling strokes</measure>
    <time_frame>30 days, one and two years from implantation procedure</time_frame>
    <description>Disabling stroke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Implantation success</measure>
    <time_frame>immediately after the procedure</time_frame>
    <description>implantation attempt resulting in proper implant position immediately after the procedure without any device/procedure related complication that requires surgery or endovascular treatment for correction, or that results in death or major disability</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of properly positioned implants</measure>
    <time_frame>one and two years from implantation procedure</time_frame>
    <description>Proper implant position in each CCA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of observed thrombi on the device</measure>
    <time_frame>30 days, one and two years from implantation procedure</time_frame>
    <description>Thrombus on implant detected by ultrasound imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of death cases</measure>
    <time_frame>one and two years from implantation procedure</time_frame>
    <description>Death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of strokes (any kind)</measure>
    <time_frame>one and two years from implantation procedure</time_frame>
    <description>Total number of strokes</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Stroke</condition>
  <arm_group>
    <arm_group_label>Vine™ Filter + OAC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vine™ Filter in each common carotid artery (CCA) with oral anticoagulant treatment (either vitamin K antagonist (VKA) or novel oral anticoagulant (NOAC)) for the duration of the study</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Vine™ Embolic Protection System</intervention_name>
    <description>The system includes the implant and the Vine™ Inserter (inserter) manufactured by Javelin Medical LTD (Israel). The inserter comprises a Motor Unit and a Needle Unit (&quot;Needle Unit&quot;) available in two sizes. The system is operable when the Needle Unit is loaded with the implant (labeled &quot;Loaded Needle Unit&quot;) and connected to the Motor Unit. A flag indicating the needle orientation is attached to the needle luer. The implant is automatically deployed from the needle upon activation of the operating button.</description>
    <arm_group_label>Vine™ Filter + OAC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Documented AF&#xD;
&#xD;
          -  CHA2DS2-VASc score ≥ 4 and history of ischemic stroke (including TIA with positive&#xD;
             neuro-imaging)&#xD;
&#xD;
          -  No contra-indication for patient to receive an OAC, either vitamin K antagonist (VKA)&#xD;
             or novel oral anticoagulant (NOAC) for the duration of the study&#xD;
&#xD;
          -  Age &gt; 50 years&#xD;
&#xD;
          -  Maximal (systolic) CCA diameter range: ≥ 4.8mm and ≤ 9.8mm&#xD;
&#xD;
          -  CCA accessibility: up to 40mm from skin to CCA center, safe approach&#xD;
&#xD;
          -  Implantation segment free of atherosclerotic disease as determined by ultrasound&#xD;
             imaging&#xD;
&#xD;
          -  Patient is able and willing to provide informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Evidence of carotid stenosis &gt; 30% [CCA, internal carotid artery (ICA), or external&#xD;
             carotid artery (ECA)]&#xD;
&#xD;
          -  Evidence of carotid dissection&#xD;
&#xD;
          -  Pre-existing stent(s) in CCA&#xD;
&#xD;
          -  Female who is pregnant or who is planning to become pregnant during the course of the&#xD;
             study&#xD;
&#xD;
          -  Life expectancy of less than two years&#xD;
&#xD;
          -  Active systemic infection&#xD;
&#xD;
          -  Known sensitivity to nickel or titanium metals, or their alloys&#xD;
&#xD;
          -  Known hereditary or acquired coagulation disorders&#xD;
&#xD;
          -  Any planned surgical or endovascular treatment within 30 days after the implantation&#xD;
             procedure&#xD;
&#xD;
          -  A co-morbid disease or condition that could confound the neurological and functional&#xD;
             evaluations or compromise survival or ability to complete follow-up assessments*&#xD;
             Current use or a recent history of illicit drug(s) use or alcohol abuse (defined as&#xD;
             regular or daily consumption of more than four alcoholic drinks per day)&#xD;
&#xD;
          -  Active participation in another investigational drug or device treatment study&#xD;
&#xD;
          -  Inability to complete all scheduled follow-up&#xD;
&#xD;
          -  Any other condition that in the opinion of the investigator may adversely affect the&#xD;
             safety of the patient or would limit the patient's ability to complete the study&#xD;
&#xD;
          -  History of intracerebral hemorrhage (ICH) and/or hemorrhagic stroke&#xD;
&#xD;
          -  Event of stroke/TIA in the past 14 days&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sagit Broder, M.Sc</last_name>
    <phone>972-4-7701267</phone>
    <phone_ext>206</phone_ext>
    <email>sagit@javelinmed.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>maria Berson, B.Sc</last_name>
    <phone>972-4-7701270</phone>
    <phone_ext>209</phone_ext>
    <email>Maria@javelinmed.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>OLV Ziekenhuis</name>
      <address>
        <city>Aalst</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tom De Potter, M.D</last_name>
      <email>tom.de.potter@olvz-aalst.be</email>
    </contact>
    <contact_backup>
      <last_name>Hedwig Batjoens</last_name>
      <email>Hedwig.Batjoens@OLVZ-aalst.be</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>ZNA Stuivenberg</name>
      <address>
        <city>Antwerp</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefan Verheye, M.D</last_name>
      <email>stefan.verheye@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Na Homolce Hospital</name>
      <address>
        <city>Prague</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Petr Neuzil, M.D.</last_name>
      <email>Petr.Neuzil@homolka.cz</email>
    </contact>
    <contact_backup>
      <last_name>Petr Moucka</last_name>
      <email>Petr.Moucka@homolka.cz</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Alfried-Krupp Krankenhaus Rüttenscheid</name>
      <address>
        <city>Essen</city>
        <zip>45131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ronald Veltkamp, M.D</last_name>
      <email>roland.veltkamp@krupp-krankenhaus.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cardio Vasculäres Centrum Frankfurt</name>
      <address>
        <city>Frankfurt</city>
        <zip>60389</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Horst Sievert, M.D</last_name>
      <email>horst@sievert.md</email>
    </contact>
    <contact_backup>
      <last_name>Sabine deBruijn</last_name>
      <email>s.debruijn@cvcfrankfurt.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Cardioangiologisches Centrum Bethanien</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Boris Schmidt, M.D</last_name>
      <email>b.schmidt@ccb.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>General Hospital of Athens &quot;Hippokrateio&quot;</name>
      <address>
        <city>Athens</city>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Konstantinos Toutouzas, M.D</last_name>
      <email>ktoutouz@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Laiko Hospital</name>
      <address>
        <city>Athen</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Athanasios PROTOGEROU, M.D.</last_name>
      <email>aprotog@med.uoa.gr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University General Hospital of Larisa</name>
      <address>
        <city>Larissa</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>George Ntaios, M.D</last_name>
      <email>ntaiosgeorge@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>European Interbalkan Medical Center</name>
      <address>
        <city>Thessaloníki</city>
        <zip>57001</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Apostolos Tzikas, M.D</last_name>
      <email>aptzikas@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gottsegen György Hungarian Institute of Cardiology</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Geza Fontos, M.D</last_name>
      <email>geza.fontos@kardio.hu</email>
    </contact>
    <contact_backup>
      <last_name>Orsolya Nagy</last_name>
      <email>zs.nagyorsi@gmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Carmel</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ofer Galili, M.D</last_name>
      <email>offerga@clalit.org.il</email>
    </contact>
    <contact_backup>
      <last_name>Ariela Goldberg</last_name>
      <email>arielago1@clslit.org.il</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Shaari Tzedek</name>
      <address>
        <city>Jerusalem</city>
        <zip>9103102</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yaron Almagor, M.D</last_name>
      <email>almagor@szmc.org.il</email>
    </contact>
    <contact_backup>
      <last_name>Michel Glikson</last_name>
      <email>mglikson@szmc.org.il</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Rabin Medical Center (RMC)</name>
      <address>
        <city>Petah tikva</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rani Barnea, M.D</last_name>
      <email>raniba@clalit.org.il</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Poria</name>
      <address>
        <city>Tiberias</city>
        <zip>1520800</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ibrahim Marai, M.D</last_name>
      <email>imarai@poria.health.gov.il</email>
    </contact>
    <contact_backup>
      <last_name>Jana Etkin</last_name>
      <email>JEtkin@poria.health.gov.il</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Szpital Kliniczny Przemienienia Pańskiego Uniwersytetu Medycznego im. Karola Marcinkowskiego w Poznaniu, Pracownia Hemodynamiki Serca</name>
      <address>
        <city>Poznań</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maciej Lesiak, M.D</last_name>
      <email>maciej.lesiak@skpp.edu.pl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramon y Cajal</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jaime Masjuan, M.D</last_name>
      <email>jaime.masjuan@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Czechia</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Poland</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>March 21, 2019</study_first_submitted>
  <study_first_submitted_qc>March 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 27, 2019</study_first_posted>
  <last_update_submitted>August 24, 2021</last_update_submitted>
  <last_update_submitted_qc>August 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AF</keyword>
  <keyword>Stroke</keyword>
  <keyword>Filter</keyword>
  <keyword>Emboli</keyword>
  <keyword>Carotid</keyword>
  <keyword>OAC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

